Universal Biosensors Pty. Ltd. of Rowille /Victoria at MEDICA 2022 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Company news

Date

Topic

29 Jul 2022

UBI signs 2 new distribution deals in Europe, first sales in the UK and launches Glucose Test

Universal Biosensors, Inc. (ASX: UBI) is pleased to announce that it has entered into non-exclusive Distribution Agreements with Generon S.p.A. (Italy) & Biomedica Medizinprodukte GmbH (Austria & eastern Europe) for the distribution of its wine testing platform device, Sentia.

More Less

19 Apr 2022

Tn Antigen: Peter Mac Interim Development Clinical Study Results

Universal Biosensors, Inc. (ASX:UBI) is pleased to announce interim results from the Peter Mac sponsored Tn Antigen1 “Development Clinical Study” (initially announced on 14 September 2021).
UBI is developing a handheld portable Tn Antigen cancer biosensor using a “finger prick” blood test to accurately measure changes to a cancer patient’s tumor status (monitoring of remission and reoccurrence) delivering easier, cheaper, and more frequent tests. The Tn Antigen biosensor test could be used by oncologists and cancer patients in clinics, hospitals, GP clinics or at home.

More Less

28 Feb 2022

Regulatory Approval to sell Xprecia PrimeTM in 32 countries in Europe

Universal Biosensors, Inc. (ASX:UBI) is pleased to announce it has been granted regulatory approval to sell its next generation handheld PT/INR coagulation testing platform, Xprecia PrimeTM, in 32 countries across Europe.

More Less

Please log in

You must be logged in to use matchmaking